Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Aligos Therapeutics, Inc. (ALGS : NSDQ)

• Company Description    Aligos Therapeutics, Inc. is a clinical stage biopharmaceutical company. It is focused on the development of antiviral therapies for chronic hepatitis B and coronaviruses as well as liver diseases. Aligos Therapeutics, Inc. is based in SAN FRANCISCO, Calif. Number of Employees: 93

• Price / Volume Information    Yesterday's Closing Price: $1.10 Daily Weekly Monthly 20 Day Moving Average: 427,793 shares Shares Outstanding: 42.69 (millions) Market Capitalization: $46.97 (millions) Beta: 3.52 52 Week High: $34.31 52 Week Low: $1.03 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -20.86% -10.86% 12 Week -54.92% -50.44% Year To Date -90.73% -88.68%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL ONE CORPORATE DR. 2ND FLOOR - SOUTH SAN FRANCISCO,CA 94080 USA ph: 800-466-6059 fax: - cdavis@lifesciadvisors.com http://www.aligos.com

• General Corporate Information    Officers Lawrence M. Blatt - Chief Executive Officer and Director Leonid Beigelman - President and Director Lesley Ann Calhoun - Executive Vice President; Chief Financial Officer K. Peter Hirth - Director Jack B. Nielsen - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 01626L105 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/22 Next Expected EPS Date: 08/04/22 Share - Related Items Shares Outstanding: 42.69 Most Recent Split Date: (:1) Beta: 3.52 Market Capitalization: $46.97 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.64 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-2.95 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 5.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/04/22

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.31 Price/Cash Flow: - Price / Sales: 7.80 EPS Growth vs. Year Ago Period: -13.51% vs. Previous Quarter: 5.62% Sales Growth vs. Year Ago Period: 182.53% vs. Previous Quarter: 600.54% ROE 03/31/22 - -75.34 12/31/21 - -67.03 09/30/21 - -62.43 ROA 03/31/22 - -59.20 12/31/21 - -54.33 09/30/21 - -51.31 Current Ratio 03/31/22 - 4.72 12/31/21 - 5.25 09/30/21 - 7.15 Quick Ratio 03/31/22 - 4.72 12/31/21 - 5.25 09/30/21 - 7.15 Operating Margin 03/31/22 - -2,263.64 12/31/21 - -2,944.02 09/30/21 - - Net Margin 03/31/22 - -2,263.64 12/31/21 - -2,944.02 09/30/21 - - Pre-Tax Margin 03/31/22 - -2,261.16 12/31/21 - -2,940.79 09/30/21 - -3,121.67 Book Value 03/31/22 - 3.58 12/31/21 - 4.33 09/30/21 - 5.09 Inventory Turnover 03/31/22 - - 12/31/21 - - 09/30/21 - - Debt-to-Equity 03/31/22 - 0.00 12/31/21 - 0.00 09/30/21 - 0.00 Debt-to-Capital 03/31/22 - 0.15 12/31/21 - 0.14 09/30/21 - 0.02

Powered by Zacks Investment Research ©